Hope Hicks, the former White House communications director once considered to be a confidante to Donald Trump, was called to testify on Friday in Trump's historic hush money trial. Her testimony ...
Jurors in former President Donald Trump's criminal trial in New York heard testimony Monday about how the business records at the center of the case were crafted, with attorneys questioning two ...
Trump's former top aide was the top witness on Day 11 of his hush money trial. Hope Hicks testifies at Trump hush money trial Former President Donald Trump is on trial in New York City ...
In the hush money trial against the former president, prosecutors called two witnesses Monday who worked in accounting in the Trump Organization: Jeffrey McConney, a former Trump Org. controller ...
A former top executive at the Trump Organization took the witness stand in Donald Trump's criminal trial Monday to describe his role in the payments the former president made that led to charges ...
NEW YORK — Salacious celebrity scandal peppered with foundation-building evidence defined the second week of testimony in former President Trump’s New York criminal trial. Witnesses this week ...
The witness list in Donald Trump's criminal trial is getting long, and the evidence list is even longer. The former president is on trial for 34 counts of falsifying business records to disguise ...
Catch up on latest news out of Donald Trump’s criminal trial for hush-money payments to adult film star Stormy Daniels Donald Trump is the first former US president to be tried on criminal ...
It is the first criminal trial of a former president. By Ben Protess, Kate Christobek and Jonah E. Bromwich Follow our live coverage of Trump’s hush money trial in Manhattan. Donald J.
UPDATE: The hush money trial against former President Donald Trump is underway in New York. It started April 15 and is expected to last weeks. The trial is not being televised. You can find the ...
In this phase 1 trial, Hegde et al. treat 13 individuals with advanced sarcoma with lymphodepletion followed by HER2-specific CAR T cells, which were found to be safe and showed antitumor activity.
In an open-label phase 2 trial, patients with non-small-cell lung cancer received neoadjuvant anti-PD-1 with or without anti-LAG-3, showing that curative intent surgery after combined blockade of ...